Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin

A 54-year-old man presented with diffuse bleeding and thrombosis and was initially considered to have immune thrombocytopenia and, later, disseminated intravascular coagulation. Ultimately, the condition was determined to be due to a platelet-activating antiplatelet factor 4 (anti-PF4) disorder, pre...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Woo Hwang, William B. Ershler
Format: Article
Language:English
Published: American College of Physicians 2024-06-01
Series:Annals of Internal Medicine: Clinical Cases
Online Access:https://www.acpjournals.org/doi/10.7326/aimcc.2024.0095
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850202552899993600
author Min Woo Hwang
William B. Ershler
author_facet Min Woo Hwang
William B. Ershler
author_sort Min Woo Hwang
collection DOAJ
description A 54-year-old man presented with diffuse bleeding and thrombosis and was initially considered to have immune thrombocytopenia and, later, disseminated intravascular coagulation. Ultimately, the condition was determined to be due to a platelet-activating antiplatelet factor 4 (anti-PF4) disorder, preceded by an upper respiratory infection in the absence of prior heparin use. The heparin antibody assay showed a highly positive titer at 2.301 OD, with a strongly positive serotonin release assay at 78% with 0.1 U/mL unfractionated heparin, confirming the diagnosis. We successfully managed the postviral anti-PF4 disorder with intravenous immunoglobulin, in addition to anticoagulation with argatroban.
format Article
id doaj-art-3554c2c4702d4b88b4ebaf147fd506a7
institution OA Journals
issn 2767-7664
language English
publishDate 2024-06-01
publisher American College of Physicians
record_format Article
series Annals of Internal Medicine: Clinical Cases
spelling doaj-art-3554c2c4702d4b88b4ebaf147fd506a72025-08-20T02:11:45ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642024-06-013610.7326/aimcc.2024.0095Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous ImmunoglobulinMin Woo Hwang0William B. Ershler11Internal Medicine Residency Program, Inova Fairfax Medical Campus, Falls Church, Virginia2Department of Hematology and Medical Oncology, Inova Fairfax Hospital, Fairfax, VirginiaA 54-year-old man presented with diffuse bleeding and thrombosis and was initially considered to have immune thrombocytopenia and, later, disseminated intravascular coagulation. Ultimately, the condition was determined to be due to a platelet-activating antiplatelet factor 4 (anti-PF4) disorder, preceded by an upper respiratory infection in the absence of prior heparin use. The heparin antibody assay showed a highly positive titer at 2.301 OD, with a strongly positive serotonin release assay at 78% with 0.1 U/mL unfractionated heparin, confirming the diagnosis. We successfully managed the postviral anti-PF4 disorder with intravenous immunoglobulin, in addition to anticoagulation with argatroban.https://www.acpjournals.org/doi/10.7326/aimcc.2024.0095
spellingShingle Min Woo Hwang
William B. Ershler
Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
Annals of Internal Medicine: Clinical Cases
title Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
title_full Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
title_fullStr Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
title_full_unstemmed Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
title_short Postviral Platelet-Activating Anti-PF4 Disorder Responsive to High-Dose Intravenous Immunoglobulin
title_sort postviral platelet activating anti pf4 disorder responsive to high dose intravenous immunoglobulin
url https://www.acpjournals.org/doi/10.7326/aimcc.2024.0095
work_keys_str_mv AT minwoohwang postviralplateletactivatingantipf4disorderresponsivetohighdoseintravenousimmunoglobulin
AT williambershler postviralplateletactivatingantipf4disorderresponsivetohighdoseintravenousimmunoglobulin